Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/Ib Open-Label, Multi-Center, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of Intravenous NBF 006 in Patients With Non-Small Cell Lung, Pancreatic, or Colorectal Cancer Followed by a Dose Expansion Study in Patients With KRAS-Mutated Non-Small Cell Lung Cancer

NCT03819387 is registered in ClinicalTrials.gov with Nitto BioPharma, Inc. as lead sponsor.

NCT NCT03819387
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03819387 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/Ib Open-Label, Multi-Center, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of Intravenous NBF 006 in Patients With Non-Small Cell Lung, Pancreatic, or Colorectal Cancer Followed by a Dose Expansion Study in Patients With KRAS-Mutated Non-Small Cell Lung Cancer
Lead sponsor
Nitto BioPharma, Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 18, 2019
Completion date
March 12, 2024
Enrollment
49 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, non-small cell lung cancer, pancreatic cancer